These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 37388769)

  • 1. Emerging advances in nanobiomaterials-assisted chimeric antigen receptor (CAR)-macrophages for tumor immunotherapy.
    Zhang Y; Yang J; Zhang T; Gu H
    Front Bioeng Biotechnol; 2023; 11():1211687. PubMed ID: 37388769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing cellular immunotherapy with macrophages.
    Mishra AK; Malonia SK
    Life Sci; 2023 Sep; 328():121857. PubMed ID: 37307965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Nanoimmunotherapy by Modulating Tumor-Associated Macrophages for Cancer Therapy.
    Hao J; Zhao X; Wang C; Cao X; Liu Y
    Bioconjug Chem; 2024 Jul; 35(7):867-882. PubMed ID: 38919067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy approaches.
    Unver N
    Clin Exp Med; 2023 Nov; 23(7):3171-3177. PubMed ID: 37278931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
    Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
    Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumor-associated macrophages as an antitumor strategy.
    Cheng N; Bai X; Shu Y; Ahmad O; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
    Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
    Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-macrophage: A new immunotherapy candidate against solid tumors.
    Chen Y; Yu Z; Tan X; Jiang H; Xu Z; Fang Y; Han D; Hong W; Wei W; Tu J
    Biomed Pharmacother; 2021 Jul; 139():111605. PubMed ID: 33901872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
    Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
    Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.
    Santoni M; Massari F; Montironi R; Battelli N
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188547. PubMed ID: 33932561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
    Zuo YH; Zhao XP; Fan XX
    Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors.
    Huo Y; Zhang H; Sa L; Zheng W; He Y; Lyu H; Sun M; Zhang L; Shan L; Yang A; Wang T
    J Transl Med; 2023 Mar; 21(1):225. PubMed ID: 36978075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T therapy for ovarian cancer: Recent advances and future directions.
    Xin Q; Chen Y; Sun X; Li R; Wu Y; Huang X
    Biochem Pharmacol; 2024 Jun; 226():116349. PubMed ID: 38852648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.